Study of AZD1222 for the Prevention of COVID-19 in Japan

Study identifier:D8111C00002

ClinicalTrials.gov identifier:NCT04568031

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

Medical condition

COVID-19

Phase

Phase 1/2

Healthy volunteers

Yes

Study drug

AZD1222, 0.9% (w/v) saline

Sex

All

Actual Enrollment

256

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 23 Aug 2020
Primary Completion Date: 22 Nov 2021
Study Completion Date: 22 Nov 2021

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Prevention

Verification:

Verified 01 Jul 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

IQVIA

Inclusion and exclusion criteria